|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | 根据甲状腺癌危险程度分层行放射性碘治疗和选择性靶向治疗显示文摘亲碘是分化型甲状腺癌的典型表现,可用放射性碘对该肿瘤进行有效治疗。在大多数分化型甲状腺癌患者中,常采用放射性碘来清除残留甲状腺组织(简称清甲),对于这类患者主张用最小有效剂量。辅助治疗可降低分化型甲状腺癌复发风险,但相关患者的最佳纳入标准及具体治疗剂量尚不清楚。进展期分化型甲状腺癌患者能从最大放射性碘耐受剂量的治疗中获益。筛选适合清甲的患者及其治疗剂量是近期研究热点之一。近年来研发出一些用于治疗碘抵抗难治性分化型甲状腺癌的靶向药物,其中一种已通过美国食品与药品管理局(FDA)的批准,此外,多个临床试验正在评估单用靶向药物或靶向药物联合放射性碘治疗难治性分化型甲状腺癌的疗效。 | 董萍 李林 Daniel A. Pryma Susan J. Mandel | 2018 | 中华核医学与分子影像杂志2018，38，5： | 7 |
| 2 | Targeted delivery of antibody -based therapeutic and imaging agents to CNS tumors:Crossing the blood - brain - barrier divide显示文摘 | Chacko AM Li C Pryma DA | 2013 | Expert Opinion On Drug Delivery2013，10，7： | 1 |
| 3 | Parathyroid Imaging显示文摘 | Fakharan S Branstetter BF Pryma DA | 2008 | Neuroimaging Clin N Am2008，18，3： | 1 |
| 4 | Diagnostic and prognostic application of positron emission tomography in breast imaging:emerging uses and the role of PET in monitoring treatment response显示文摘 | Cintolo JA Tchou J Pryma DA | 2013 | Breast Cancer Res Treat2013，138，2： | 1 |
| 5 | Effect of cuhivar, year grown, and cropping system on the content of tocopherols and tocotrienols in grains of hulled and hulless barley 显示文摘 | Ehrenbergerova J Belcrediova N Pryma J Vaculova K Newman C W | 2006 | Plant Foods for Human Nutrition2006，61，： | 1 |
| 6 | Prognostic value of primary tumor FDG uptake for occult mediastlnal lymph node involvement in clinically N2/N3 node-negative non-small cell lung cancer显示文摘 | Trister AD Pryma DA Xanthopoulos E | 2014 | AmJClin Oncol2014，37，2： | 1 |
| 7 | Effect of cuhivar, year grown, and cropping system on the content of tocopherols and tocotrienols in grains of hulled and hulless barley 显示文摘 | Ehrenbergerova J Belcrediova N Pryma J | 2006 | Plant Foods for Human Nutrition2006，61，3： | 1 |
| 8 | Diagnostic accuracy and prognostic value of ^18F-FDG PET in Hurthle cell thyroid cancer patients显示文摘 | Pryma DA Schoder H Gonen M | 2006 | J Nucl Med2006，47，8： | 1 |
| 9 | Drainage characteristics and differential function of the horseshoe kidney: what is typical 显示文摘 | Stockton BR Pryma DA Smaldone MC | 2008 | Endourol2008，22，6： | 1 |
| 10 | Parathyroid Imaging显示文摘 | Fakharan S Branstetter BF Pryma DA | 2008 | Neuroimaging Clin N Am2008，18，： | 1 |
| 11 | Diagnostic accuracy and prognostic value of 18F -FDG-PET in Hurthle cell thyroid cancer patients显示文摘 | PRYMA D A SCHODER H GONEN M | 2006 | J Nucl Med2006，47，8： | 1 |
| 12 | Correlation of in vivo and in vitro measures of carbonic anhydrase IX antigen expression in renal masses using antibody 124I-cG250显示文摘 | Pryma DA O'Donoghue JA Humm JL | | 0，，04： | 1 |
| 13 | Diagnostic accuracy and prognostic value of 18F-FDG PET in Hurthle cell thyroid cancer pa- tients显示文摘 | Pryma DA Schoder H Gonen M | 2006 | J Nucl Med2006，47，8： | 1 |
| 14 | Diagnostic accuracy and prognostic value of 18F-FDG PET in Htirthle cell thyroid cancer patients 显示文摘 | Pryma DA Schoder H Gonen M | 2006 | J Nucl Med2006，47，8： | 1 |
| 15 | A phase I trial of the HIV protease inhibitor neltinavir with concurrent che- moradiotherapy (CT-RT) for unresectable stage IIIA,/IIIB non-small cell lung cancer: a report of toxicities and clin- ical response 显示文摘 | RENGAN R MICK R PRYMA D | 2012 | Journal of Thoracic Oncology2012，7，4： | 1 |
| 16 | Parathyroid imaging 显示文摘 | Fakhran S Branstetter BF Pryma DA | 2008 | Neuroimaging Clin N Am2008，18，3： | 1 |
| 17 | Preliminary data from an ongoing phase IIb study of no carrier added 131 I-iobenguane(nca-MIBG) in patients with malignant pheochromocytoma (Pheo)显示文摘 | Pryma D A Barrett J A Coleman R E | 2011 | Clin Oneol (Meeting Abstracts)2011，29，21： | 1 |
| 18 | Molecular imaging biomarkers for oncology clinical trials显示文摘 | Mankoff DA Pryma DA Clark AS | 2014 | J Nucl Med2014，55，4： | 1 |
| 19 | PET/CT imaging in cancer : current applications and future directions 显示文摘 | Farwell MD Pryma DA Mankoff DA | 2014 | Cancer2014，120，22： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员